Beneficial Impact of Vaccination Against SARS-CoV-2 on the Mental Health of IPF Patients

Beneficial Impact of Vaccination Against SARS-CoV-2 on the Mental Health of IPF Patients

<b>Background</b>: Depression and anxiety represent significant comorbidities in idiopathic pulmonary fibrosis (IPF) patients, affecting their quality of life. The COVID-19 pandemic has had an uneven impact on global mental health. The Hospital Anxiety and Depression Scale (HADS) constit...

Full description

Saved in:
Bibliographic Details
Main Authors: Ioannis Tomos, Andriana I. Papaioannou, Zoe I. Daniil, Ilias E. Dimeas, Paraskevi Kirgou, Athena Gogali, Konstantinos Tatsis, Ilias Papanikolaou, Vasilios Tzilas, Argyrios Tzouvelekis, Panayiota Tsiri, Paschalis Steiropoulos, Pachalis Ntolios, Areti Xyfteri, Katerina Antoniou, Emmanouil Symvoulakis, Aggeliki Haritou, Maria Maniati, Lykourgos Kolilekas, Elvira-Markella Antonogiannaki, Vasiliki Apollonatou, Maria Kallieri, Kostas Samaras, Stylianos Loukides, Anna Karakatsani, Demosthenes Bouros, Effrosyni Manali, Spyros Papiris
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Advances in Respiratory Medicine
Subjects:
mental health
depression
anxiety
Idiopathic pulmonary fibrosis
vaccination against COVID-19
vaccines
Online Access:https://www.mdpi.com/2543-6031/92/6/42
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<b>Background</b>: Depression and anxiety represent significant comorbidities in idiopathic pulmonary fibrosis (IPF) patients, affecting their quality of life. The COVID-19 pandemic has had an uneven impact on global mental health. The Hospital Anxiety and Depression Scale (HADS) constitutes a validated tool to identify anxiety disorders and depression. The aim of this multicentre study was to evaluate the effect of COVID-19 vaccination on depression and anxiety in IPF patients. <b>Methods</b>: Consecutive IPF patients (median 73.5 years) who are regularly followed-up with were included in the study. Demographics, functional, and clinical were recorded. The HADS score was calculated before and one month after vaccination against COVID-19 in all participants. A Wilcoxon signed ranks test was conducted. <b>Results</b>: A total of 180 IPF patients (median 73.5 years) were included in the study. Among them, 145 patients (81%) received antifibrotic treatment. A significant reduction in HADS, both in anxiety and depression scales, was observed one month after vaccination against SARS-COV-2), independent of age, smoking, lung function impairment, and prior history of depression (<i>p</i> < 0.01). <b>Conclusions</b>: A higher Hospital Anxiety and Depression Scale score was detected before vaccination against COVID-19. It seems that vaccination also offered a beneficial effect on depression and anxiety in IPF patients, independent of age, smoking, lung function impairment, and prior history of depression.
ISSN:2543-6031

Similar Items